MRC2 and sarcoma: To evaluate if the anti-Endo180 mAb A5/158, which recognizes an epitope in CTLD2 (Fig. 1A; ref. 31), is a suitable candidate for development into an ADC, we assessed its binding specificity in multiple sarcoma cell lines.